Accessibility Menu
Medicenna Therapeutics logo

Medicenna Therapeutics(TSX) MDNA

Current PriceCA$0.35
Market CapCA$27.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-87%
5 Year-88%
1 Year-57%
1 Month-16%
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 0.352026-07-22
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.11%CAD 0.372026-07-15
1 month-15.66%CAD 0.422026-06-22
3 month-38.6%CAD 0.572026-04-23
Year to date-61.96%CAD 0.922025-12-31
1 year-56.79%CAD 0.812025-07-22
3 year-37.5%CAD 0.562023-07-21
5 year-87.97%CAD 2.912021-07-23
Since inception-87.04%CAD 2.702017-03-08

Medicenna Therapeutics Financials at a Glance

Market Cap

CA$27.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$18.41M

EPS (TTM)

-CA$0.22

P/E Ratio

-1.58

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$0.35

Volume

1,571

Open

CA$0.36

Previous Close

CA$0.35

Daily Range

CA$0.35 - CA$0.36

52-Week Range

CA$0.34 - CA$1.97

Estimated Earnings Date

Jul 30, 2026

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is an innovative immunotherapy company dedicated to developing and commercializing Superkines and "empowered Superkines" for cancer treatment and other diseases. The company’s lead candidate, MDNA55, has completed Phase IIb trials for recurrent glioblastoma and is being explored for various tumor types.

Products and Services
  • MDNA55: An interleukin-4 empowered cytokine for glioblastoma
  • MDNA11: An improved IL-2 variant targeting cancer
  • BiSKITs platform: Custom-engineered Superkines for therapeutic applications
Growth Outlook
  • MDNA55 shows promise in ongoing clinical trials, potentially expanding market opportunities
  • Pipeline includes multiple candidates addressing various cancers and autoimmune diseases
  • Strategic partnerships may enhance research capabilities and accelerate development timelines
Financial Highlights
  • Recent quarterly net income of -$4.23 million, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $6.25 million as of March 31, 2026, supporting operational needs
  • Trailing twelve months (TTM) cash flow from operations indicates a focus on long-term growth despite losses
Medicenna Therapeutics Corp. operates in the biotechnology sector, focusing on advanced immunotherapy solutions. The company’s innovative approach to cancer treatment through Superkines positions it uniquely in a competitive market. With a robust pipeline and ongoing clinical trials, Medicenna aims to address significant unmet medical needs. The financial data reflects a commitment to research and development, which is crucial for long-term success in the biotechnology industry. The current cash position provides a foundation for continued operations and development efforts, while the strategic outlook suggests potential for future growth and partnerships.
AI Generated • Jul 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-219.30%

Return on Capital

-911.57%

Return on Assets

-217.75%

Earnings Yield

-63.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$27.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.62M

Volume

1.57K

Avg. Volume

94.49K

Financials (TTM)

Gross Profit

-CA$77.00K

Operating Income

-CA$23.71M

EBITDA

-CA$23.05M

Operating Cash Flow

-CA$17.92M

Capital Expenditure

CA$9.44M

Free Cash Flow

-CA$13.45M

Cash & ST Invst.

CA$6.25M

Total Debt

CA$119.00K

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.16-62.7%
20242024-03-31CAD -0.37135.6%
20252025-03-31CAD -0.15-57.9%
20262026-03-31CAD -0.2243.7%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-492.8%
Q22025-09-302.0%
Q32025-12-3110.6%
Q42026-03-312.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$19.00K

+0.0%

Gross Margin

0.00%

N/A

Market Cap

CA$27.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.36M

N/A

Employees

20

N/A

Net Income

-CA$4.23M

-456.7%

EBITDA

-CA$7.10M

-24.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$6.25M

-74.8%

Total Debt

CA$119.00K

-29.2%

Accounts Receivable

CA$1.35M

-50.1%

Inventory

CA$0.00

N/A

Long Term Debt

CA$54.00K

-54.6%

Short Term Debt

CA$65.00K

-33.7%

Return on Assets

-2.18%

N/A

Return on Invested Capital

-7.93%

N/A

Free Cash Flow

CA$0.00

+100.0%

Operating Cash Flow

-CA$4.48M

+10.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MIR.VMedMira Inc.
CA$0.06-14.29%
SVA.TOSernova Corp.
CA$0.12-0.00%
COV.VCovalon Technologies Ltd.
CA$2.16+2.86%
ZEN.VZentek Ltd.
CA$0.74-5.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.90-0.28%
AALAmerican Airlines Group
$13.65-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$65.57-0.07%
TAT&T
$22.83-0.01%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at CA$0.35 per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between CA$0.34 and CA$1.97.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$119.00K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$6.25M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services